Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma

INTRODUCTION: A patient who was initially considered to have a glioblastoma (GBM) had molecular analysis, showing that it was a pleomorphic xanthoastrocytoma (PXA). Up to 78% of PXA tumors have BRAF V600E mutations. Primary brain tumors with BRAF mutations can have a good response to BRAF MEK inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Piña, Yolanda, Fusco, Michael J., Macaulay, Robert J., Walko, Christine M., Peguero, Edwin, Evernden, Brittany R., Smalley, Keiran S., Forsyth, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035305/
https://www.ncbi.nlm.nih.gov/pubmed/31748891
http://dx.doi.org/10.1007/s00415-019-09575-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035305/
https://www.ncbi.nlm.nih.gov/pubmed/31748891
http://dx.doi.org/10.1007/s00415-019-09575-8

Ejemplares similares